Agreement signedPublished 27 Oct 2025

Biossil Inc. /
Galera Therapeutics, Inc.

Biossil Inc. signed an agreement for Galera Therapeutics, Inc.

Buy side: Biossil Inc.
Buy sideBiossil Inc.
Target: Galera Therapeutics, Inc.
TargetGalera Therapeutics, Inc.
Galera Therapeutics, Inc. · 27 Oct 2025Source
Buy side: Biossil Inc.
Buy sideBiossil Inc.
Target: Galera Therapeutics, Inc.
TargetGalera Therapeutics, Inc.
01 / BuyerBiossil Inc.
02 / TargetGalera Therapeutics, Inc.
Source for the buyer and target: Galera Therapeutics, Inc.

For the buyer and target.

target

“The term “ Blackstone Agreement ” means the Amended and Restated Purchase and Sale Agreement, dated as of November 14, 2018, by and among Galera Therapeutics, Inc. (the “ Company ”), Clarus IV Galera Royalty AIV, L.P. and each of the entities identified on Schedule 1 thereto, as amended by Amendment No. 1 thereto, dated May 11, 2020, and the Second Amendment thereto, dated August 27, 2025.”

Published 27 Oct 2025

Open the source
01

What happened

The deal for Galera Therapeutics, Inc. is signed, with Biossil Inc. as the buyer. [01]

The filing from Galera Therapeutics, Inc. is dated Oct. 27, 2025. [01]

02

The source

Everything on this page comes from the source below, quoted word for word.

01
Source · Galera Therapeutics, Inc.

Biossil Inc. signed an agreement for Galera Therapeutics, Inc.

This document is the source for the companies, stage and people on this page.

Open the source
03

Timeline

Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.

  1. Announced

    “The filing from Galera Therapeutics, Inc. is dated Oct. 27, 2025”

    Open the source
  2. Published by Galera Therapeutics, Inc.

    The source this page is built from.

    Open the source

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Get ProAlready a member? Sign in

Pro is open to everyone.